Kök Mert, Röder Franziska, Bokkers Reinoud P H, Uyttenboogaart Maarten, Gareb Barzi, Zeebregts Clark J
Departments of Surgery (Division of Vascular Surgery), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Radiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
J Endovasc Ther. 2025 Jun 21:15266028251325054. doi: 10.1177/15266028251325054.
Carotid artery restenosis can occur after both carotid artery stenting (CAS) and carotid endarterectomy (CEA). This systematic review and meta-analysis aim to determine which revascularization technique, CAS, or CEA, is superior for treating primary carotid restenosis, irrespective of the initial revascularization method used.
Systematic review and meta-analysis.
MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRALs) databases were searched for eligible studies on December 19th, 2023. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was followed. Primary endpoint was the occurrence of transient ischemic attack (TIA) or any stroke. Secondary endpoints were technical success, death within 30 days, myocardial infarction (MI), local complications, cerebral hyperperfusion syndrome (CHS), cranial nerve injury (CNI), dys-/arrythmia, secondary restenosis, repeat revascularization, and long-term survival. Results were adjusted for symptomatic status and primary treatment strategy.
Nineteen studies comprising 10,171 procedures in 10,041 patients were included. Baseline characteristics were comparable between groups. Main findings were (1) No difference in primary outcome; however, if adjusted for symptomatic status the rate of TIA/any stroke is higher (OR: 2.05, 95% CI: 1.29-3.27, p < 0.01) after CEA compared to CAS; (2) Significant higher rate of MI (OR: 1.85, 95% CI: 1.19-2.86, p < 0.01) after CEA; (3) Besides CNI, which appears to be commonly temporary and occurred only after CEA (7.56%, 95% CI: 4.21%-13.22%), no significant differences in other secondary endpoints were observed between groups. Long-term risk of secondary restenosis was similar between CEA compared to CAS (OR: 0.98, 95% CI: 0.39-2.49, p = 0.95); (4) Correction for the index procedure did not affect conclusions.
Based on limited-quality studies, mostly retrospective and nonrandomized in design, both CAS and CEA represent feasible treatment approaches for patients with primary restenosis, with comparable primary outcome between the two groups. However, based on the obtained results, CAS appears to be preferable. Patients should be critically evaluated in a multidisciplinary team and further research is desirable.Clinical ImpactThis review expands on previous studies by incorporating a larger patient cohort and more recent literature while offering new insights into restenosis. Unlike earlier research, this study uniquely evaluates first repeat revascularization outcomes (CAS and CEA) independently of the initial procedure, suggesting that patient and plaque characteristics might be more influential than the primary technique. Sensitivity analysis confirmed this, as stratification by index procedure did not alter conclusions. Although lower TIA/stroke and mortality rates were observed in CAS-treated patients, these findings were not statistically significant in the overall group. These results may help guide clinical decision-making for optimal restenosis management.
颈动脉支架置入术(CAS)和颈动脉内膜切除术(CEA)后均可能发生颈动脉再狭窄。本系统评价和荟萃分析旨在确定哪种血运重建技术,即CAS或CEA,在治疗原发性颈动脉再狭窄方面更具优势,而不考虑最初使用的血运重建方法。
系统评价和荟萃分析。
于2023年12月19日检索MEDLINE、EMBASE和Cochrane对照试验中心注册库(CENTRALs)数据库以查找符合条件的研究。遵循系统评价和荟萃分析的首选报告项目(PRISMA)声明。主要终点是短暂性脑缺血发作(TIA)或任何卒中的发生情况。次要终点包括技术成功率、30天内死亡、心肌梗死(MI)、局部并发症、脑过度灌注综合征(CHS)、颅神经损伤(CNI)、心律失常、继发性再狭窄、再次血运重建以及长期生存率。结果根据症状状态和初始治疗策略进行了调整。
纳入了19项研究,共涉及10041例患者的10171例手术。各组间基线特征具有可比性。主要发现如下:(1)主要结局无差异;然而,若根据症状状态进行调整,与CAS相比,CEA后TIA/任何卒中的发生率更高(比值比:2.05,95%置信区间:1.29 - 3.27,p < 0.01);(2)CEA后MI发生率显著更高(比值比:1.85,95%置信区间:1.19 - 2.86,p < 0.01);(3)除了CNI似乎通常为暂时性且仅在CEA后发生(7.56%,95%置信区间:4.21% - 13.22%)外,各组间在其他次要终点方面未观察到显著差异。与CAS相比,CEA后继发性再狭窄的长期风险相似(比值比:0.98,95%置信区间:0.39 - 2.49,p = 0.95);(4)对初次手术进行校正并不影响结论。
基于质量有限的研究,大多为回顾性且设计非随机,CAS和CEA对原发性再狭窄患者而言均是可行的治疗方法,两组间主要结局具有可比性。然而,根据所得结果,CAS似乎更可取。患者应在多学科团队中进行严格评估,且需要进一步研究。临床影响本评价通过纳入更大的患者队列和更新的文献扩展了先前的研究,同时为再狭窄提供了新的见解。与早期研究不同,本研究独特地独立于初始手术评估首次再次血运重建结局(CAS和CEA),表明患者和斑块特征可能比主要技术更具影响力。敏感性分析证实了这一点,因为按初次手术分层并未改变结论。尽管在接受CAS治疗的患者中观察到较低的TIA/卒中率和死亡率,但在总体组中这些发现无统计学意义。这些结果可能有助于指导针对最佳再狭窄管理的临床决策。